REG - Craven House Capital - Investee company update: Bio Vitos

Craven House CapitalAnnouncement

23/10/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231023:nRSW9418Qa&default-theme=true

RNS Number : 9418Q  Craven House Capital PLC  23 October 2023

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION
(EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE
OF THE EU (WITHDRAWAL) ACT 2018.

Craven House Capital plc

("Craven House" or the "Company")

Investee company update: Bio Vitos

Further to the announcement of 3 July 2023 at 01:32pm Craven House announces
that the transaction between its investee company, Bio Vitos, and Hemcheck
Sweden AB ("Hemcheck") has received approval from Nasdaq Stockholm. Bio Vitos
will now proceed to completion of the transaction which is anticipated during
September, 2023. Upon completion  Bio Vitos will  own 259,654,000 shares in
Hemcheck.. This amounts to  88.3% of Hemcheck's share capital.

 Craven House's holding in Bio Vitos will remain unchanged.

The full text of the announcement released by Hemcheck today has been
translated and set out below:

" PRESS RELEASE

Hemcheck has been conditionally approved for continued listing by Nasdaq and
can complete the transaction with Bio Vitos

Hemcheck has been approved for continued listing by Nasdaq, subject to the
transaction with Bio Vitos being carried out and other customary conditions
such as updating the website after the transaction is completed.

With this, the company description that has been produced is published and
this can also be found on the company's website, www.hemcheck.se. This also
means that the transaction with Bio Vitos, where IP rights and capital are
acquired, can be completed.

The company will quickly implement all the steps required to complete the
transaction with Bio Vitos. Additional information will be shared as soon as
final dates are determined.

 

 

For further information please contact:

 Craven House Capital Plc                                                Tel: 0203 286 8130

 Mark Pajak

 www.Cravenhousecapital.com (http://www.cravenhousecapital.com/)

 SI Capital                                                              Tel: 01483 413500

 Broker

 Nick Emerson

 www.sicapital.co.uk (http://www.sicapital.co.uk/)

 SPARK Advisory Partners Limited                                         Tel: 0203 368 3550

 Nominated Adviser

 Matt Davis/James Keeshan

 www.Sparkadvisorypartners.com (http://www.sparkadvisorypartners.com/)

 

About Craven House Capital:

The Company's Investing Policy is primarily to invest in or acquire a
portfolio of companies, partnerships, joint ventures, businesses or other
assets participating in the e-Commerce sector.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PFUEXLBLXBLXFBX